Search - tctmd.com

Displaying 41 - 59 of 59

Sort: Relevancy | Date

People Living in Amazon Rainforest Provide Clues to Coronary Protection

News Conference News ACC 2017

People Living in Amazon Rainforest Provide Clues to Coronary Protection

March 17, 2017

Transcatheter Aortic Valve Replacement with a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients: First Results from the SURTAVI Clinical Trial

Presentation ACC 2017

First Results from the SURTAVI Clinical Trial

Presenter: Michael J. Reardon

March 17, 2017

SPIRE 1 and 2: Support for PCSK9 Inhibition but Not Bococizumab

News Conference News ACC 2017

SPIRE 1 and 2: Support for PCSK9 Inhibition but Not Bococizumab

Yael L. Maxwell

March 17, 2017

Live From Washington: ACC 2017, Day One

News Conference News ACC 2017

Live From Washington: ACC 2017, Day One

March 17, 2017

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

News Conference News ACC 2017

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

March 17, 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk

Presentation ACC 2017

Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk

Presenter: Marc Sabatine

March 17, 2017

To Stent or Not to Stent? iFR vs FFR Late Breakers at ACC 2017 Seek to Shake Up Treatment Decisions

News Conference News ACC 2017

To Stent or Not to Stent? iFR vs FFR Late Breakers at ACC 2017 Seek to Shake Up Treatment Decisions

March 14, 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

March 10, 2017

HDL Cholesterol

News Conference News ACC 2017

Low HDL Cholesterol Common in Young MI Patients, With Young Women Faring Worse Long-Term

Michael O'Riordan

March 10, 2017

Does Hormone Replacement Therapy Curb Atherosclerosis? New Imaging Study Opens Old Questions

News Conference News ACC 2017

Does Hormone Replacement Therapy Curb Atherosclerosis? New Imaging Study Opens Old Questions

March 09, 2017

Down and Out: Depressed CAD Patients Twice as Likely to Die as Those Without Depression

News Conference News ACC 2017

Down and Out: Depressed CAD Patients Twice as Likely to Die as Those Without Depression

March 09, 2017

More Certainty With Ceramides? New Blood Test May Help ID CAD Patients Early in Disease

News Conference News ACC 2017

More Certainty With Ceramides? New Blood Test May Help ID CAD Patients Early in Disease

Yael L. Maxwell

March 09, 2017

Erectile Dysfunction Meds Linked to Fewer Death and HF Hospitalizations After MI

News Conference News ACC 2017

Erectile Dysfunction Meds Linked to Fewer Death and HF Hospitalizations After MI

March 09, 2017

Sodium Restriction Message Not Getting Through to Hypertensive Patients

News Conference News ACC 2017

Sodium Restriction Message Not Getting Through to Hypertensive Patients

March 08, 2017

News Conference News ACC 2016

DANAMI3: Deferred Stenting, Ischemic Postconditioning No Help in STEMI

April 04, 2016

SAPIEN 3 Transcatheter Aortic Valve Replacement Compared with Surgery in Intermediate-Risk Patients: A Propensity Score Analysis

Presentation ACC 2016

SAPIEN 3 Transcatheter Aortic Valve Replacement Compared with Surgery in Intermediate-Risk Patients: A Propensity Score Analysis

Presenter: Vinod Thourani

April 01, 2016

News Conference News ACC 2015

SCOT-HEART Provides Support for Coronary CTA in Angina Management

March 15, 2015

Conference ACC 2017

ACC 2017

Washington, DC

March 17, 2017

March 19, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.